Cathie Wood Stock Portfolio: 5 Newest Stock Picks This Year

2. Moderna, Inc. (NASDAQ:MRNA)

Ark Investment’s Stake Value: $19 million

Percentage of Ark Investment’s 13F Portfolio: 0.13%

Number of Hedge Fund Holders: 45

Moderna, Inc. (NASDAQ:MRNA) is an American biotechnology firm that uses messenger ribonucleic acid (RNA) technology to develop therapies for infectious diseases, heart diseases, cancer, and immune system disorders. The firm is headquartered in Cambridge, Massachusetts.

As this year’s third quarter ended, Ark Investment had bought 163,592 Moderna, Inc. (NASDAQ:MRNA) shares for a $19 million stake which represented 0.13% of its investment portfolio. Insider Monkey’s Q2 2022 survey of 895 hedge funds saw 45 as having invested in the firm.

Not only is Moderna, Inc. (NASDAQ:MRNA) responsible for manufacturing perhaps the most advanced coronavirus vaccine in the world, but the firm is also developing a cancer vaccine for melanoma patients with the pharmaceutical giant Merck and the firms expect to report data from trials during the ongoing quarter.

Moderna, Inc. (NASDAQ:MRNA)’s largest investor in our database is Patrick Degorce’s Theleme Partners which owns 6.3 million shares that are worth $907 million.

Baron Funds mentioned the company in its Q3 2022 investor letter. Here is what the fund said:

“Within biotechnology, underperformance of Moderna, Inc. (NASDAQ:MRNA) and lower exposure to this better performing sub-industry weighed the most on relative performance. Shares of Moderna, a leader in the emerging field of mRNA-based vaccines and therapeutics, declined due to increasing uncertainty around what a booster market could look like as COVID shifts away from pandemic status and becomes an increasingly commercial market rather than government funded.”